More Industry News

  • AstraZeneca partners with Torrent to launch branded generics

    AstraZeneca agreed to brand and market 18 generic drugs owned by Torrent Pharmaceuticals in nine emerging markets. "The products were carefully selected in therapy areas we're strong in. We believe we can be successful in building market share and brand equity," said Renaud Savary, head of AstraZeneca's branded-generics unit.

    Read more

  • Cel-Sci receives Byron's marketing fee for cancer drug candidate

    Byron Biopharma paid a marketing fee of $125,000 to Cel-Sci as part of a partnership for Multikine, the latter's drug candidate for head and neck cancers. In March 2009, Cel-Sci agreed to grant Byron rights to market and distribute the treatment in South Africa.

    Read more

  • GSK is evaluating acquisitions in India, CEO says

    GlaxoSmithKline is considering deals to buy or work with Indian drugmakers, according to this article. In a Q-and-A, CEO Andrew Witty said the company will reduce the price of its drugs in India to extend its reach with low-income consumers. The drugmaker will also collaborate with local companies to cut production costs, Witty said. GSK is interested in acquisitions to increase its business in India, but only at the right price, he said.

    Read more

  • Ischemix begins Phase IIa trial of drug for tissue damage

    Ischemix started a Phase IIa trial of CMX-2043, an injectable treatment for a form of tissue damage called ischemia-reperfusion injury. The biotech firm hopes to become the first company to launch such a cardio-protective drug in the U.S.

    Read more

  • Novartis takes option for Transgene's cancer vaccine

    Novartis paid $10 million for an exclusive option to develop Transgene's cancer vaccine TG4010. Transgene could receive as much as $950 million in milestone payments, but the biotech firm will continue funding development until Novartis decides whether to exercise the option.

    Read more

  • Takeda pays Affymax $5 million for anemia drug's milestone

    Affymax said it secured a milestone fee of $5 million from Takeda Pharmaceutical in connection with the launch of a late-stage trial in Japan of Hematide, the former's anemia drug candidate for patients with chronic renal failure. The companies are working on the development and commercialization of the drug in the U.S.

    Read more

Powered by SmartBrief